Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in

KRAS drug resistance signal transduction

Journal

Proceedings of the National Academy of Sciences of the United States of America
ISSN: 1091-6490
Titre abrégé: Proc Natl Acad Sci U S A
Pays: United States
ID NLM: 7505876

Informations de publication

Date de publication:
27 Feb 2024
Historique:
medline: 20 2 2024
pubmed: 20 2 2024
entrez: 20 2 2024
Statut: ppublish

Résumé

The Kirsten rat sarcoma viral oncogene homologue

Identifiants

DOI: 10.1073/pnas.2319492121 PMID: 38377196
pubmed: 38377196
doi: 10.1073/pnas.2319492121
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2319492121

Subventions

Organisme : Dutch Cancer Society
ID : N/A
Organisme : Heparegenix
ID : N/A

Déclaration de conflit d'intérêts

Competing interests statement:W.A. and R.S. are employees of HepaRegeniX. W.A. and L.Z. are shareholders of HepaRegeniX. R.B. received research funding from HepaRegeniX. R.S., W.A., and S.A.L. are listed as inventors of the small molecule MAP2K4 inhibitor used here.

Auteurs

Robin A Jansen (RA)

Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.

Sara Mainardi (S)

Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.

Matheus Henrique Dias (MH)

Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.

Astrid Bosma (A)

Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.

Emma van Dijk (E)

Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.

Roland Selig (R)

HepaRegeniX GmbH, Tuebingen 72072, Germany.

Wolfgang Albrecht (W)

HepaRegeniX GmbH, Tuebingen 72072, Germany.

Stefan A Laufer (SA)

Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmaceutical Sciences, Eberhard Karls Universität Tübingen, Tübingen 72074, Germany.
Tübingen Center for Academic Drug Discovery and Development, Tübingen 72074, Germany.
Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies" (EXC 2180), Eberhard Karls Universität Tübingen, Tübingen 72076, Germany.

Lars Zender (L)

Tübingen Center for Academic Drug Discovery and Development, Tübingen 72074, Germany.
Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies" (EXC 2180), Eberhard Karls Universität Tübingen, Tübingen 72076, Germany.
Department of Medical Oncology and Pneumology, University Hospital Tübingen, Tübingen 72076, Germany.
German Cancer Research Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.

René Bernards (R)

Division of Molecular Carcinogenesis, Oncode Institute, The Netherlands Cancer Institute, Amsterdam 1066 CX, The Netherlands.
ORCID: 0000-0001-8677-3423

Classifications MeSH